Mesotheliemo Treatment
Once a patient receives a diagnosis of mesotheliemo, extensive treatment starts immediately. The goal is to halt the progression of the disease. This includes standard cancer responses such as surgery, radiation, and/or chemotherapy.
As with all cancer surgeries, there are risks associated with surgery, dependent upon the patient’s overall health. There have been many cases of patients having success with surgery, but is a highly individualized protocol. Much depends on the location, size and number of tumors. As with all cancer, radiation is an option, based on several other factors. However, the primary treatment is chemotherapy; it’s been shown to improve the surgery outcome as well as radiation, and in several ways. Assorted chemotherapy drugs work by either destroying cancerous cells or preventing them from multiplying. Some allow a malignant tumor to shrink, which may make surgery more productive. It could also destroy remaining, microscopic cells in the body after a cancerous growth is removed. In addition, chemotherapy may also slow the spreading of mesotheliemo and decrease physical pain.
Most physicians prescribe combination treatments to maximize patient success. For those patients with a compromised physical condition, chemotherapy is their primary treatment. Mesotheliemo requires a tolerance to the drugs, and fortunately there are many from which to choose. There are also a few recommended combination approved by the Food and Drug Administration to directly target mesotheliemo.
Like all drugs, chemotherapy can cause undesired side effects in their goal to eradicate bad cells. Its presence in the body means that healthy cells get destroyed as well as the malignant ones. Since certain cells in the digestive tract (mouth, esophagus, stomach and intestine) have a high reproduction rate, chemotherapy patients often suffer nausea, vomiting, diarrhea, constipation, mouth sores, and appetite and hair loss. Patients also report other uncomfortable side effects, such as numbness and tingling of hands and feet, ringing in the ears. All unusual symptoms must be reported as soon as possible. Even unusual fatigue should be noted, as it could be a reaction from the heart, lungs, kidney, bladder or liver. Cell modifications in bone marrow may also result in heavy bleeding from small injuries, and could compromise the patient’s immune system.
Since it’s vital to get chemotherapy drugs into a patient quickly, within a limited time frame, care must be taken to maximize the tolerable amount. Drug toxicity and patient endurance are balanced to prevent a patient stopping treatment prematurely and losing accrued benefits. The majority of mesotheliemo treatments require a minimum of 3 chemotherapy visits, and doses are often revised after two months. Many factors affect the type and dosages of chemotherapy, such as the patient’s age, overall health, type of drug, stage of disease, and reactions to the drug. Side effects cease upon discontinuance of chemotherapy, such as if the disease appears stabilized. If the patient’s condition worsens, chemotherapy is usually discontinued and alterative treatments begun.
Many patients often receive chemotherapy through a catheter into the chest or abdominal cavity. This allows the medicine direct contact with the cancerous tumor. Normally, this is done for 130 minutes every 21 days, but may be supplemented with other injections. Patients must eat healthy food to avoid weight loss, drink a high volume of liquids, and avoid individuals with colds or the flu.
Alimta is the first FDA approved chemotherapy drug for mesotheliemo and is often utilized for pleural mesotheliemo, or for patients unable to tolerate surgery. Currently, alimta and capsulation are used in the optimum combination. Alimta inhibits thymidine and purine synthesis, and thus blocks cell division. When used with capsulation, it increases a patient’s lifespan than when used alone, but it must be used in conjunction with oral steroids, B12, and folic acid. Another combination is capsulation and gemcitabine. Patients on this regime realize more weight gain and improved respiratory function. The mix utilizes gemcitabine’s anti-metabolite, DNA-cessation properties along with cisplatin’s poisonous effects. Capsulation is occasionally partnered with the anti-cancer drug doxorubicin (or vinblastine and mitomycin), but other popular pairings are capsulation, doxorubicin and cyclophosphamide, as well as vincristine and methotrexate.
Non-poisonous drugs include raltitrexed, which interferes with the tumor cells’ ability to create DNA, onconase, which interrupts protein synthesis, and vinorelbine, which blocks cell division. All are also used in the fight mesotheliemo.
